( MENAFN - EIN Presswire) MIAMI, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its positive long-term transplant-free survival data from a multi-year follow-on study to the ELPIS I Phase 1 clinical trial were featured in an oral presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting taking place October 27-28, 2024 in Chicago, Illinois.
“HLHS is a devastating disease for patients and their families, so I am impressed and very encouraged to see the continued long-term survival of patients treated with Lomecel-BTM in the ELPIS I study,” said Sunjay Kaushal, M.D., Ph.
D., Professor of Surgery, Cardiovascular and Thoracic Surgery at University of Nevada, Las Vegas.“Even with current comprehensive treatment, only 50% to 60% of infants survive to adolescence due to right ventricular failure and for those that are surviving, parents are strongly seeking to avoid transplant.
There is clearly an important unmet medical need to improve right ventricular function in these infants to positively impact both short- and long-term patient outcomes, and stem cell therapy, particularly Lomecel-BTM, has the potential to play a critical role in treating these patients.” ELPIS I was an open-label, Phase 1 clinical trial designed to evaluate the safety of Lomecel-BTM in patients with HLHS. Patients underwent the Glenn Procedure (an open-heart surgery).
